according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

SECTION 1. IDENTIFICATION

Product name : Halofuginone Formulation Other means of identification : HALOCUR (A009802)

HALOCUR ORAL SOLUTION FOR TREATMENT OF

CALVES (57163)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Skin irritation : Category 2

Eye irritation : Category 2A

GHS label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : H315 Causes skin irritation.

H319 Causes serious eye irritation.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P280 Wear protective gloves, eye protection and face protec-

tion.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

P332 + P313 If skin irritation occurs: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.
P362 + P364 Take off contaminated clothing and wash it before

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

reuse.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Lactic acid	50-21-5	>= 1 - < 5
Halofuginone	82186-71-8	< 0.1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

Protection of first-aiders

delayed

Causes skin irritation.

Causes serious eye irritation.

First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Specific hazards during fire

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

Specific extinguishing meth-

ucts

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Carbon oxides

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Advice on safe handling

Use only with adequate ventilation.

Do not get on skin or clothing.

Avoid inhalation of vapor or mist.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Halofuginone	82186-71-8	TWA	5 μg/m3 (OEB 4)	Internal	
	Further information: DSEN, Skin				
		Wipe limit	50 μg/100 cm ²	Internal	

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not

exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : yellow

Odor : odorless

Odor Threshold : No data available

pH : 2.1 - 3

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

ions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Method: Calculation method

Components:

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Halofuginone:

Acute oral toxicity : LD50 (Rat): 30 mg/kg

LD50 (Mouse): 5 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.053 mg/l

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 16 mg/kg

Skin corrosion/irritation

Causes skin irritation.

Components:

Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Halofuginone:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Components:

Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

Halofuginone:

Result : Severe irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Lactic acid:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Halofuginone:

Routes of exposure : Dermal Species : Guinea pig Result : Sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Remarks: Based on data from similar materials

Halofuginone:

Genotoxicity in vitro : Test Type: Ames test

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Test Type: Cytogenetic assay

Species: Rat

Application Route: Oral Result: negative

Test Type: DNA Repair Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

Halofuginone:

Species : Mouse Application Route : Oral

NOAEL : 0.24 mg/kg body weight

Result : negative

Species : Rat

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Application Route : Oral Exposure time : 63 weeks

NOAEL : 0.36 mg/kg body weight

Result : negative

Species : Rat
Application Route : Oral
Exposure time : 26 Months

NOAEL : 0.09 - 0.18 mg/kg body weight

Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

Application Route: Ingestion

Result: negative

Halofuginone:

Effects on fertility : Test Type: Fertility

Species: Mouse Application Route: Oral

Fertility: NOAEL: 0.126 mg/kg body weight

Result: No effects on fertility.

Test Type: Fertility Species: Dog

Application Route: Oral

Fertility: LOAEL: 0.067 mg/kg body weight

Result: Effects on fertility.

Test Type: Three-generation reproduction toxicity study

Species: Mouse Application Route: Oral

General Toxicity F1: LOAEL: 0.063 mg/kg body weight

Symptoms: Reduced body weight

Result: No effects on fertility and early embryonic

development were detected.

Effects on fetal development : Test Type: Embryo-fetal development

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 0.34 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 0.67 mg/kg body weight Result: No embryo-fetal toxicity., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 0.025 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 0.076 mg/kg body weight Result: No embryo-fetal toxicity., No teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Halofuginone:

Target Organs : Blood

Assessment : Causes damage to organs through prolonged or repeated

exposure

Repeated dose toxicity

Components:

Lactic acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Remarks : Based on data from similar materials

Species : Rat
LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

Halofuginone:

Species : Mouse
NOAEL : 0.07 mg/kg
LOAEL : 0.16 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

Species : Rat

NOAEL : 0.13 mg/kg
LOAEL : 0.88 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Species : Dog

NOAEL : 0.067 mg/kg LOAEL : 0.134 mg/kg Application Route : Oral

Exposure time : 13 Weeks
Target Organs : Blood

Species : Dog

NOAEL : 0.075 mg/kg
LOAEL : 0.16 mg/kg
Application Route : Oral
Exposure time : 26 Weeks

Not classified based on available information.

Experience with human exposure

Components:

Target Organs

Aspiration toxicity

Halofuginone:

General Information : No human information is available.

Blood

Inhalation : Remarks: May cause irritation of respiratory tract.
Skin contact : Remarks: May cause skin irritation and/or dermatitis.

May cause sensitization by skin contact.

Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

plants mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

Halofuginone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1.8 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

LC50 (Cyprinus carpio (Carp)): 0.3 mg/l

Exposure time: 72 h

Remarks: Based on data from similar materials

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.12 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.02 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

EC50 (Chlorella pyrenoidosa): 46 mg/l Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Persistence and degradability

Components:

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

Halofuginone:

Biodegradability : Result: Not readily biodegradable.

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version **Revision Date:** SDS Number: Date of last issue: 09/30/2023 12/08/2023 845725-00021 Date of first issue: 08/26/2016 6.3

Bioaccumulative potential

Components:

Lactic acid:

Partition coefficient: n-

octanol/water

: log Pow: -0.62

Halofuginone:

Partition coefficient: n-

octanol/water

log Pow: 1.18

Mobility in soil

Components:

Halofuginone:

Distribution among environ- : log Koc: 3.87 mental compartments

Method: FDA 3.08

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version 6.3

Revision Date: 12/08/2023

SDS Number: 845725-00021

Date of last issue: 09/30/2023 Date of first issue: 08/26/2016

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Skin corrosion or irritation

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Water 7732-18-5 Benzoic acid 65-85-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information


according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 6.3 12/08/2023 845725-00021 Date of first issue: 08/26/2016

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory: TECI - Thailand Existing Chemicals Inventory: TSCA - Toxic Substances Control Act

according to the OSHA Hazard Communication Standard



Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 12/08/2023 845725-00021 Date of first issue: 08/26/2016 6.3

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date 12/08/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8